Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human parathyroid hormone (1-34) in postmenopausal osteoporosis – Phase II dose–response study
CTR20132957Phase 2Completed
- Sponsor
- Shanghai Zhongke Shenglongda Biotechnology
- Start
- May 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of teriparatide in postmenopausal osteoporosis, sponsored by Shanghai Zhongke Shenglongda Biotechnology. Started May 2014; status: completed.
02
Drugs
teriparatide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on CTR20132957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132957.